Market Newsdesk

CARLSBAD, Calif., April 21, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release first quarter financial results after the close of trading on Monday, May 3, 2021. Members of the Company’s management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1036925. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact

Leigh Salvo
(415) 937-5402
[email protected]

SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it had received more than $30 million to support space-related U.S. national security efforts. The follow-on awards are to previous contracts, implementing advanced technologies to provide better system performance.  

“Kratos enables technological approaches and modernization that were not possible even a few years ago, but can now support this program for many years to come with the inherent flexibility to upgrade and evolve at the speed of relevance,” commented Senior Vice President Frank Backes. “Kratos’ broad space portfolio is focused on technology-leading products and services that realize the DoD’s vision of data being an asset. These advanced capabilities are scalable, flexible and resilient; allowing real-time data to flow from multiple domains in support of national defense.”

Phil Carrai, President of Kratos’ Space, Training and Cybersecurity Division, said, “Space is undergoing a renaissance. Advancements in ground systems and satellite technologies are joining to form space networks that support multi-domain missions and broader data requirements. Kratos is leading the digital transformation on the ground side by introducing into space networks proven technologies from other network-centric industries. Not only does this enhance performance and affordability for the DoD, it opens doors for the defense industry to better integrate with and capitalize on commercial space enterprises as well.”

Due to competitive, customer-related and other considerations, no additional information will be provided.

About Kratos Defense & Security Solutions

Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops and fields transformative, affordable technology, platforms and systems for United States National Security related customers, allies and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information go to www.KratosDefense.com.

Notice Regarding Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 27, 2020, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:

Yolanda White
858-812-7302 Direct

Investor Information:

877-934-4687
[email protected] 

ATLANTA, April 21, 2021 (GLOBE NEWSWIRE) — By:Matt Davis, Director of Tax Credit Investments

Corporations Aggressively Pursuing ESG Profiles

Today more than ever, public corporations are actively seeking to improve their ESG profiles. There are multiple ways to forward this agenda, from reducing their carbon footprints to diversifying their workforces and boards to improving their transparency for their investors and actively improving the communities in which they operate.

One powerful tool that corporations can utilize to further this agenda is investment in renewable energy tax credit partnerships. This allows a company to direct capital earmarked for Federal tax liabilities towards investment in a partnership that develops and operates renewable energy projects. A $25mm tax equity investment would facilitate solar installations with the capacity of adding 66,000 KWdc of clean, renewable energy to the power grid. Over the lifetime of such a project, this is the equivalent of 350,000 homes’ electricity use per year or removing 465,000 passenger cars from the road annually.

Accounting Approach is Hindering ESG Investments

The Federal government is encouraging investment in renewable energy through tax credit programs, and corporations are looking for ways to move in greener directions, creating a powerful alignment of interests. In the last decade alone, solar has experienced an average annual growth rate of 49 percent, according to data from the Solar Energy Industries Association. There are now more than 89 gigawatts (GW) of solar capacity installed nationwide, enough to power 16 million homes. Given the huge positive impact these projects create for corporate investors and their communities, one might expect broad institutional participation in these investments. Why is this not the case? The answer, certainly in part, lies in accounting treatment. Accounting firms, particularly the traditional big four, are requiring that their clients utilize a highly inefficient and complex approach to account for these investments. This accounting treatment results in reporting which inaccurately reflects the economics of the investment and in some instances may result in investment losses reported above the line, adversely and artificially impacting operating earnings. This adverse accounting treatment is materially hampering investment at this critically important moment. The Financial Accounting Standards Board (FASB) should take note and remove a significant roadblock to investment.

In November 2000, the American Institute of Certified Public Accountants (AICPA) released an Exposure Draft Proposed Statement of Position (SOP) entitled Accounting for Investors’ Interests in Unconsolidated Real Estate Investments. The purpose of the SOP was to offer a framework where partners in real estate and private equity deals could determine the valuation of their stake in the event of a liquidation of the partnership. One of the concerns the authors sought to address was how to deal with variable interest investments. The backdrop at the time were the Enron-generated accounting issues which emerged with difficult valuations of complicated partnership interests. The mechanism introduced was called Hypothetical Liquidation at Book Value (HLBV). HLBV’s goal is to value variable interests (ownership interests that change over time) in partnerships during the life of the partnership. As its name would suggest, it does so by assuming the partnership liquidates at its book value at the end of each reporting period and the interests are valued based on what they would receive under such hypothetical liquidation under the terms of the partnership agreement. This is a sensible approach to more accurately reflect the value of interests in partnership investments where the underlying partnership interests and value of partnership assets change. 

The modern-day solar ITC partnership flip transaction, which is the typical ITC partnership structure, was developed many years ago, pre-dating the HLBV SOP. Nevertheless, HLBV is ill-suited for use with tax equity ITC partnerships. In the typical tax equity ITC investment, the vast majority of the investor’s return is the receipt of federal ITCs. In the case of solar ITC, it’s all received in the initial year of the investment. The tax equity investor may receive additional cash distributions over the following years, but they are modest compared to the ITC. In the case of solar ITC, recapture is so rare as to be statistically insignificant but would occur if the partnership was liquidated prior to the expiration of the five-year recapture period.  After the expiration of the five-year recapture period, the tax equity’s investor interest in the partnership “flips” from 99% to 5% and typically is redeemed from the entity shortly thereafter. The tax equity partner’s retention of a 99% interest for the first five years of the partnership is to avoid recapture of ITC received in the first year, not because of some expectation of significant economic benefit from the underlying project. 

Applying HLBV methodology to tax equity ITC investments illogically skews income recognition and results in a distortion of the economic reporting of the investment for GAAP reporting purposes. Under a hypothetical liquidation of the investment, ITC recapture would result, and the tax equity investor would receive the bulk of the value of the partnership’s book valued assets to compensate for the loss of the ITC under most partnership agreements. Under both the deferral and the pass-through method of equity accounting, the partnership’s investment would be written down to a very small number upon the receipt of the ITC. This would be an appropriate result given the limited remaining economic return expected by the tax equity investor. However, HLBV would write the investment back up close to its original value based on its use of a hypothetical liquidation to determine the value of the underlying partnership interests. This would result in grossly overstated income and assets in the initial year and overstated above-the-line losses in the succeeding five years. In any ITC partnership, early liquidation is not an option. While partners may have good reason, economic or otherwise, to dissolve a real estate partnership, there is never a reason justifying a liquidation that would trigger ITC recapture.

Public corporations who seek to participate in solar ITC partnerships are often compelled to apply HLBV and the harmful GAAP losses that frequently accompany its use. HLBV creates EPS volatility that can be prohibitive for meaningful investment in solar ITC. Accounting firms are challenged to find a more appropriate methodology to address this partnership issue and, for their part, are actively working with their clients to minimize the adverse impacts that can result from HLBV implementation. Companies are forced to choose between opportunities that support ESG and green initiatives, and the price stability of their shareholder’s stock.

Is there a better way?

The partnership flip structure that governs the majority of solar ITC partnerships could be better served by an accounting methodology already used in another corner of the tax credit universe. The Low Income Housing Tax Credit (LIHTC) program utilizes proportional amortization. FASB issued guidance on LIHTC in January 2014, enabling investors to account for the income statement effects of their investments entirely through income tax expense. FASB made these adjustments, in part, to encourage investors to support these low income housing projects, which may lack capital otherwise. This is a viable roadmap that could be followed for the solar ITC.

While this path warrants exploration, it will also likely take FASB a long time to provide investors and accounting firms with better guidance.

In the meantime, accounting firms are working with their audit clients and solar ITC developers and syndicators to structure transactions that can minimize the negative impacts of HLBV application. Often, the investment and the investment reporting are so small relative to the operations of the company that HLBV accounting can be ignored. In situations where the investment is intended to be significant, solutions are now being proposed by a number of the Big 4 firms through use of the flow-through method of equity accounting to smooth out the above-the-line impact of these investments. This requires careful consultations with consultants to formulate specific company accounting policies to better reflect the impact of these investments. The goal would be to recognize the income from these investments either over the underlying asset’s useful life or the ITC recapture period. A standardized, widely available disseminated solution would be in everyone’s economic interests.   

Final Thoughts

Tax equity ITC investments serve our national interests. Corporations are highly motivated to make these investments in furthering their own impact initiatives and are frustrated by the complications created by HLBV accounting. FASB should be actively looking to modernize methodologies that will encourage investment. The accounting industry can help investors achieve their goal to support renewable energy and properly navigate the imperfect accounting methodologies that lie in their path. 

Attachment

• Picture1

Jane Rafeedie
Monarch Private Capital
4702838431
[email protected]

AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) — Phunware, Inc. (NASDAQ: PHUN) (“the Company”), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, today announced that it has released its Data Software Development Kit (“SDK”) for Apple iOS and Google Android on GitHub so third-party mobile applications can reward consumers with PhunCoin for their data.

This important milestone, in support of the broader launch of Phunware’s Multiscreen-as-a-Service (“MaaS”) blockchain-enabled Customer Data Platform, helps brands empower consumers to take control of and be compensated for their data. By integrating this lightweight SDK, any mobile application publisher can monetize and reward their audiences by signing them up to be compensated any time their data is purchased by brands.

“It’s no secret that data has become the most valuable asset on the planet, yet consumers continue to be exploited for this vital resource without consideration and often without permission,” said Alan S. Knitowski, President, CEO and Co-Founder of Phunware. “As a pioneer in customer data monetization, we look forward to leveraging PhunCoin to usher in a new era of transparency and accountability that enables consumers to determine not only what data they share and who they share it with, but also what that data is worth.”

This release comes just one week after Phunware announced the launch of its Loyalty SDK on Apple iOS and Google Android to give mobile application publishers the ability to track and reward consumers for their engagement by issuing PhunToken. Both PhunCoin and PhunToken will be managed by PhunWallet, which will be made available for download in the coming weeks following application approvals by the Apple App Store and Google Play.

Click here
to get started today and learn how PhunCoin can help empower and engage mobile audiences at scale.

Safe Harbor Clause and Forward-Looking Statements

This press release includes forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “expose,” “intend,” “may,” “might,” “opportunity,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our reports on Forms 10-K, 10-Q, 8-K and other filings that we make with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described under “Risk Factors” in our SEC filings may not be exhaustive.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in this press release. In addition, even if our results or operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods.

About Phunware, Inc.

Everything You Need to Succeed on Mobile — Transforming Digital Human Experience

Phunware, Inc. (NASDAQ: PHUN)
, is the pioneer of Multiscreen-as-a-Service (MaaS), an award-winning, fully integrated enterprise cloud platform for mobile that provides companies the products, solutions, data and services necessary to engage, manage and monetize their mobile application portfolios and audiences globally at scale. Phunware’s Software Development Kits (SDKs) include location-based services, mobile engagement, content management, messaging, advertising, loyalty (PhunCoin & Phun) and analytics, as well as a mobile application framework of pre-integrated iOS and Android software modules for building in-house or channel-based mobile application and vertical solutions. Phunware helps the world’s most respected brands create category-defining mobile experiences, with more than one billion active devices touching its platform each month. For more information about how Phunware is transforming the way consumers and brands interact with mobile in the virtual and physical worlds, visit https://www.phunware.com, https://www.phuncoin.com, https://www.phuntoken.com, and follow @phunware, @phuncoin and @phuntoken on all social media platforms.

Phunware PR & Media Inquiries:

[email protected]
T: (512) 693-4199

Phunware Investor Relations:

Matt Glover and John Yi
Gateway Investor Relations
Email: [email protected]
Phone: (949) 574-3860

SAN DIEGO, April 21, 2021 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) announced the adoption of its Saphyr system for optical genome mapping (OGM) by two large laboratories belonging to the National Health System (NHS) of the United Kingdom. King’s College Hospital in London and the NHS Regional Genetics Laboratory in Belfast City Hospital have adopted Saphyr systems through the company’s reagent rental program, which entails a commitment to purchase consumables over time in connection with the placement of a system. Both sites are using Saphyr to characterize the genomes of patients with heme malignancies. The site in Belfast will also evaluate Saphyr for the detection of structural variants (SVs) in patients with developmental delay, infertility, rare disease, and other genetic diseases as well.

Dr. Anwar Alhaq, Lead Clinical Scientist and Deputy Clinical Director for NHS Haematology & Pathology at King’s College Hospital, London said: “Timely identification of genomic structural variants is vital for providing diagnostic, prognostic and treatment decisions for hematological malignancies. The South East Haematological Malignancy Diagnostic Service based at King’s College Hospital currently uses a combination of techniques such as karyotyping, fluorescence in situ hybridization (FISH) and SNP arrays to provide a comprehensive analysis of all cytogenetic aberrations. These techniques are expensive, labor-intensive and time consuming and require a diverse and skilled workforce.”

Dr. Alhaq added “A number of other pilot studies have already demonstrated the clinical validity of OGM for identifying SVs in both acquired and constitutional abnormalities. We are undertaking a pilot validation study of the Saphyr system to introduce a single, automated cytogenetic workflow providing high-resolution analysis of the genome in a timely manner, ultimately to benefit patient outcomes. We hope that this will ultimately replace the need for the wide range of cytogenetic methods currently used in diagnostic laboratories and will lead to a quicker turnaround time with better defined SV data.”

Dr. Shirley Heggarty, Consultant Clinical Scientist at the NHS Regional Genetics Laboratory in Belfast City Hospital said: “As part of a modernization program of the Northern Ireland Regional Genetics Laboratory (NIRGL) we were looking to refresh and update certain of our cytogenetic facilities. Currently NIRGL relies on traditional cytogenetic techniques such as karyotyping, FISH and SNP array to identify the chromosomal changes in patients. When evaluating our options for the future, what was attractive about the Saphyr system is that it has the potential to replace several different clinical tests in one assay, avoiding the need for us invest in additional multiple cytogenetic instruments, savings us time and streamlining our workflow.”

Dr. Heggarty added “The pilot study will be used to assess the clinical utility of OGM in the identification of SVs observed in patients with constitutional and acquired chromosomal abnormalities, including but not limited to developmental delay, infertility, rare disease, leukemia and lymphoma patients.”

“What we are seeing with recent adoption within the UK NHS and other sites is a validation of the change in our sales model that we adopted in the first half of 2020. Our focus is on accelerating the process for researchers to implement OGM with Saphyr to shorten the time it takes them to generate data. A faster implementation brings revenue sooner compared to a traditional capital sales cycle, and earlier access to Saphyr data may raise awareness of that data sooner,” commented Erik Holmlin, PhD, CEO of Bionano Genomics. “King’s College Hospital London is one of the largest NHS testing centers for heme malignancies and serves a diverse patient population. Meanwhile, NIRGL is the only NHS genetic testing center in Northern Ireland, providing services to that entire population. We are thrilled that these NHS centers have chosen to invest in OGM with the Saphyr system as they begin developing and validating assays on the platform along a path to modernizing their workflows. We believe their success can spark potential adoption by many other NHS testing labs across the UK.”

About Bionano Genomics

Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential for OGM with Saphyr to revolutionize cytogenetic analysis; our beliefs regarding the potential benefits of Bionano’s Saphyr technology; the significance of large SVs in genetic research; and the execution of Bionano’s strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2020 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS

Company Contact:

Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]

Investor Relations and

Media Contact:

Amy Conrad
Juniper Point
+1 (858) 366-3243
[email protected] 

BOSTON, April 21, 2021 (GLOBE NEWSWIRE) — Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violations of the federal securities laws has been filed against FibroGen, Inc. (NASDAQ: FGEN) and certain of its executives. Investors should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (617) 398-5600. The deadline to move for appointment as lead plaintiff is June 11, 2021.

After the markets closed on April 6, 2021, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. FibroGen said it would conduct a “comprehensive internal review to ensure” that such errors do not occur again. On this news, FibroGen’s shares fell $14.90 per share, or approximately 43%, to close at just $19.74 per share on April 7, 2021.

If you purchased or acquired FibroGen securities between November 8, 2019 and April 6, 2021, you are strongly encouraged to contact the nationally-recognized law firm Block & Leviton LLP (www.blockleviton.com) at (617) 398-5600, via email at [email protected], or to visit our website for information on the case. The deadline to move the Court to be appointed lead plaintiff is June 11, 2021. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com

EDISON, N.J., April 21, 2021 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTC PINK: SFOR), a cyber technology company that reduces the risk of identity theft and data breaches and a provider of innovative cyber, privacy and data protection solutions for business and home, clarifies their 10K recently put out for the year 2020.

In our recent 10K filing, the $7M deficit of the $10M seems to have had a negative reaction says Mark L. Kay, CEO of StrikeForce, whereas, it should be considered positive news given that it shows almost all toxic loans have been paid off as stated in the following footnote in the 10k and eliminated forever:

– $6.8M of the $10 mil deficit for the year that ended 12/31/2020 is made up of:

• $175K for Private Placement Costs relating to new convertible notes issued in 2020
• $605K for Debt Discount Amortization to be expensed over the life of outstanding convertible notes
• $1.19M for the Change in the Fair Value of Derivative Liabilities relating to convertible Notes that contained an embedded derivative
• $4.84M for the Loss (Net) relating to the Extinguishment of Debt relating to convertible Notes that contained an embedded derivative

Even though all toxic loans were not paid off at the end of 2020, ALL toxic loans were fully paid off or extinguished by the end of January 2021.

About StrikeForce Technologies
Inc.

StrikeForce Technologies helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. It provides powerful two-factor, “Out-of-Band” authentication, keystroke encryption along with mobile solutions. StrikeForce Technologies, Inc. (OTC PINK:SFOR) is headquartered in Edison, N.J., and can be reached at www.strikeforcetech.com, on its Twitter and Facebook pages, or by phone at (732) 661-9641 or toll-free at (866) 787-4542.

Safe Harbor Statement:

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the sales of the company’s identity protection software products into various channels and market sectors, the issuance of the company’s pending patent application, and the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the company.

Corporate Info:

StrikeForce Technologies, Inc.
Mark L. Kay
(732) 661-9641
[email protected]

StrikeForce Media

George Waller
(732) 661-9641
[email protected]

 

Atlanta, GA, April 21, 2021 (GLOBE NEWSWIRE) — Neuravest Research, a provider of AI-driven model portfolio solutions for institutional investors, today announced the launch of its Data Refinery™, a strategic partnership program that brings together an elite group of alt data providers with empirically proven predictive qualities to drive successful investment strategies.

Using Neuravest’s award winning data analytics platform, potential Data Refinery partners go through an exhaustive evaluation and vetting process to uncover their ability to consistently generate alpha. From there, Neuravest employs machine learning to construct investment strategies that can be backtested and further validated in perpetual trading market simulations. Once empirical evidence of a data set’s value has been confirmed, Neuravest can quickly bring the investment model to market via either a specialized thematic portfolio, included in a multi-strat fund, or a bespoke portfolio that meets a fund manager’s specific needs.

“Active fund managers realize that to deliver performance that can beat their benchmarks, they can no longer simply rely on the same fundamental research that is widely available to all investors,” explained Erez Katz, Neuravest co-founder and CEO. “At the same time, they understand the enormous undertaking in building out their own data science and AI capabilities. Through our Data Refinery, Neuravest does the heavy lifting for them. We select only proven data that our analysis shows can consistently deliver value. From there, we implement market-ready investment portfolios that can be used as stand-alone strategies or incorporated into a broader investment paradigm.”

While there are more than 1,000 alternative data providers available in today’s market, Neuravest’s Data Refinery focuses on what the firm found to be “best-in-class” providers of each specific data set. To date, Neuravest has identified 42 providers, including: Benzinga, Equifax, Wall Street Horizon, OWL Analytics, New Constructs, Pynk, and many others. Through the Data Refinery, data partners gain a direct distribution channel to asset management firms that would normally not be direct clients since they lack the resources, and know-how to consume and analyze raw data. In addition, the data providers receive Neuravest’s unbiased validation reports, which include white papers, technical and marketing presentations, defensible backtests, and perpetual access to a perpetually traded model portfolio that showcases their data in a live scenario. Data providers also participate in revenue sharing opportunities built on portfolio adoption and usage.

“We are pleased to be selected as a premier Neuravest Research Data Refinery partner,” said Barry L. Star, CEO of Wall Street Horizon. “It is critical for institutional investors to experience firsthand how event data like earnings date revisions can affect volatility within their portfolios. By accessing Wall Street Horizon event data on the Neuravest platform, investors can see its influence on alpha generation and how it impacts risk strategies as well.”

Environmental, social, and governance (ESG) factors have become increasingly consequential to how the world’s largest investors allocate capital and construct portfolios. Managers need a sophisticated and easy-to-use tool that identifies, monitors, and takes advantage of the risks and opportunities that ESG presents to their investment strategies,” said Benjamin Webster, CEO at Owl Analytics. “The OWL ESG Scores provide objective ESG ratings that are updated frequently for almost 30,000 global publicly listed companies. The Neuravest platform is an ideal tool to unlock the value of the OWL Scores so that managers can avoid risk and generate alpha from ESG.”

Neuravest’s Data Refinery partners represent a dynamic list that will continue to evolve as existing alternative data sets become disseminated and new ones enter the market. “In many ways, data is like oil that feeds into the machine learning combustion engine. Yet, in other ways, some data is like uranium. It’s informational value decays over time as the market discounts it,” said Eric Davidson, Neuravest’s Executive Vice President of Strategic Partnerships. “It is imperative that the Data Refinery continuously evolves and is populated only with the most valuable and predictive data sets available.”

About Neuravest

Neuravest empowers asset managers across the globe to deliver superior fund performance by applying machine learning and data science to portfolio construction and management. Launched in 2021 as a successor to Lucena Research, Neuravest takes AI-based investment insight and decision support to the next level by designing and delivering pre-configured thematic portfolios and bespoke investment models using best-in-class alternative data sources. To Learn more, visit www.neuravest.net.

Richard Franco
Forefront Communications for Neuravest Research
917.309.8951
[email protected]

Company’s specimen collection kit now available for use in COVID-19 testing in the U.S.

Sample collection kit can be used with PCR based molecular diagnostic or antigen-based testing platforms

NEW YORK, NY, April 21, 2021 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Food and Drug Administration (“FDA”) has cleared its AMPICOLLECT™ Sample Collection kit (manufactured under GMP) for distribution under Emergency Use Authorization. The AMPICOLLECT™ Sample Collection kit is now available for sample collection for COVID-19 testing protocols in the United States.

The Company’s sample collection kit has been shown to meet the FDA’s policy standard as outlined in “Enforcement Policy for Viral Transport Media during the Coronavirus Disease 2019 (COVID-19) Public Health Emergency.” The AMPICOLLECT™ kit is not only authorized for use with Enzo’s proprietary GENFLEX® molecular diagnostic platform, but can also be used for sample collection with other PCR-based molecular diagnostic platforms or antigen-based testing platforms that require the collection of upper respiratory specimens.

Enzo’s sample collection kit represents an integral part of the company’s vertically integrated strategy to develop and deliver one of the industry’s most comprehensive offerings of platforms, products and services to support needs throughout the entire workflow of clinical diagnostic testing. Enzo’s approach has involved the development of specimen collection, sample processing and testing reagents, automated instrumentation for sample preparation and testing, and the validation, scale-up of manufacturing and commercialization of these components.  

“Emergency Use Authorization for our AMPICOLLECT™ Sample Collection kit is another reflection of the strength of our open platform approach and integrated model at work,” said Elazar Rabbani, Ph.D., CEO of Enzo.  “By internally developing and manufacturing key aspects of diagnostic testing technologies, we have successfully overcome the systemic challenges that affected this sector during the COVID-19 pandemic, including supply shortages and high costs.”

For further information, please visit the FDA’s website and Enzo’s corporate website at:
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-viral-transport-media-during-covid-19

https://www.enzolifesciences.com/ENZ-GEN228/ampicollect-saline-normal/

About Enzo Biochem





 

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem’s products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Forward-Looking Statements

Except for historical information, the matters discussed in this release may be considered “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products and services, costs of goods and services, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2020. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

###
Contact:

For Enzo Biochem, Inc.

David Bench, CFO
212-583-0100
[email protected]

Media:

Holly Stevens
Berry & Company Public Relations
212-253-8881
[email protected]

Investors:

Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
[email protected]

Steve Anreder
Anreder & Company
212-532-3232
[email protected]m



OAKVILLE, Ontario, April 21, 2021 (GLOBE NEWSWIRE) — In a heartbreaking, yet important annual event, MADD Canada and its New Brunswick Chapters and Community Leaders are preparing to add new names to the New Brunswick Memorial Monument for Victims of Impaired Driving.

The memorial monument, located at Fairhaven Memorial Garden in Moncton, honours the memories of innocent victims killed in impaired driving crashes. It is currently etched with the names of 58 people.

MADD Canada is working with families of other victims to have their names added to the monument. If you have lost a loved one in an impaired driving crash and wish to have his or her name memorialized on the monument, please contact: Gloria Appleby, MADD Canada Atlantic Region Victim Services Manager at 1-866-381-8310 or [email protected]. The deadline to submit names is June 30, 2021.

“The memorial monument is a powerful and moving way to remember victims, and provides their families and friends with a safe and peaceful place to pay tribute to their loved ones,” said Ms. Appleby said.

A ceremony to honour the new names added to the monument this year, and to pay tribute to all victims of impaired driving, will be held on Sunday, September 12.

MADD Canada is committed to honouring the memories of victims, acknowledging the losses suffered by their families and friends, and reminding the public about the devastating toll of this entirely preventable crime. If you or someone you know have been a victim of an impaired driving crash and would like to learn more about MADD Canada’s Victim Services program, please contact Ms. Appleby or visit madd.ca.

For further information, please contact:
Steve Sullivan, MADD Canada Director of Victim Services at 1-866-876-5224 or [email protected]